Table 1. Patient Characteristics Depending on 3-Year Post-Recurrence Survival Status.
| Variables | Total (n = 47) n (%) or Median (IQR) | Live More than 3 Years after Recurrence (n = 8) n (%) or Median (IQR) | Death within 3 Years after Recurrence (n = 39) n (%) or Median (IQR) | P |
|---|---|---|---|---|
| Age at diagnosis, years | 59.0 (46.0–64.5) | 55.5 (47.5–65.5) | 59.0 (46.0–64.0) | 0.723 |
| Sex | 0.146 | |||
| Male | 31 (66.0) | 3 (37.5) | 28 (71.8) | |
| Female | 16 (34.0) | 5 (62.5) | 11 (28.2) | |
| Type of gastrectomy | 0.536 | |||
| Total | 13 (27.7) | 1 (12.5) | 12 (30.8) | |
| Subtotal | 34 (72.3) | 7 (87.5) | 27 (69.2) | |
| Pathologic T stage* | 0.328 | |||
| T1 | 5 (10.6) | 2 (25.0) | 3 (7.7) | |
| T2 | 6 (12.8) | 1 (12.5) | 5 (12.8) | |
| T3 | 7 (14.9) | 2 (25.0) | 5 (12.8) | |
| T4 | 29 (61.7) | 3 (37.5) | 26 (66.7) | |
| Pathologic N stage* | 0.203 | |||
| N0 | 12 (25.5) | 4 (50.0) | 8 (20.5) | |
| N1 | 3 (6.4) | 1 (12.5) | 2 (5.1) | |
| N2 | 6 (12.8) | 0 (0.0) | 6 (15.4) | |
| N3 | 26 (55.3) | 3 (37.5) | 23 (59.0) | |
| TNM stage* | 0.178 | |||
| I | 5 (10.6) | 2 (25.0) | 3 (7.7) | |
| II | 12 (25.5) | 3 (37.5) | 9 (23.1) | |
| III | 30 (63.9) | 3 (37.5) | 27 (69.2) | |
| Histopathologic subtype | 0.759 | |||
| Adenocarcinoma | 31 (66.0) | 6 (75.0) | 25 (64.1) | |
| Signet ring cell | 16 (34.0) | 2 (25.0) | 14 (35.9) | |
| Lauren histotype | 0.343 | |||
| Diffuse | 33 (70.2) | 4 (50.0) | 29 (74.4) | |
| Intestinal | 14 (29.8) | 4 (50.0) | 10 (25.6) | |
| LNR | 0.11 (0.01–0.33) | 0.01 (0.00–0.33) | 0.11 (0.05–0.33) | 0.311 |
| SUVmax | 6.3 (4.2–9.2) | 4.0 (3.3–4.7) | 7.3 (5.0–9.9) | 0.015 |
| Weight loss, % | 11.6 (8.6–15.8) | 10.3 (5.0–13.9) | 11.6 (9.8–17.5) | 0.130 |
| Hemoglobin, g/dL | 11.7 (11.1–12.6) | 11.8 (11.6–12.1) | 11.7 (10.9–12.6) | 0.671 |
| Neutrophil count, cells/uL | 3503 (2601–4894) | 2742 (2298–3497) | 3934 (2691–5338) | 0.125 |
| Lymphocyte count, cells/uL | 1317 (964–1739) | 1235 (869–1875) | 1335 (964–1739) | 0.588 |
| Platelet count, x103 cells/uL | 228 (193–275) | 221 (191–268) | 231 (193–278) | 0.887 |
| Recurrence timing | 0.035 | |||
| Early, ≤ 2 years | 30 (63.9) | 2 (25.0) | 28 (71.8) | |
| Late, > 2 years | 17 (36.1) | 6 (75.0) | 11 (28.2) | |
| First sites of recurrence | 0.192 | |||
| Locoregional recurrence only | 6 (12.8) | 2 (25.0) | 4 (10.3) | |
| Distant metastasis only | 31 (65.9) | 6 (75.0) | 25 (64.1) | |
| Locoregional and distant failure | 10 (21.3) | 0 (0.0) | 10 (25.6) |
*According to 8th AJCC staging system. AJCC = American Joint Committee on Cancer, IQR = interquartile range, LNR = ratio of number of metastatic lymph nodes to total number of harvested lymph nodes, SUVmax = maximum standardized uptake value, TNM = tumor-node-metastasis